A recent FiercePharma article discussed Moderna’s decision not to enforce its COVID-19 vaccine patents against other companies during the pandemic. Moderna’s president said the company is “quite studiously not asserting infringement” in a Wall Street Journal interview, noting that the company isn’t interested in decreasing the number of vaccines available in a pandemic.
However, it should be noted that its patents have come under scrutiny more than once during the pandemic. Earlier in the year, Moderna failed to invalidate an Arbutus Biopharma patent that may affect their launch. Public Citizen claims the U.S. government has partial claim to Moderna’s COVID-19 patents and notes that U.S. taxpayers will end up paying for the vaccine twice: once for initial research, and again for procurement of doses.
See it Live at PACK EXPO Connects Nov. 9-13: Bulk Vial Processing – Discover our Innovative and Award Winning solutions to maximize product yield for medium and large scale processing, by groninger USA LLC. Preview the Showroom Here.